Intuitive Surgical consensus stays robust, shares anchored in the S&P 500 healthcare space

Intuitive Surgical opens the week with a solid analyst consensus and a clear profile in minimally invasive surgery, while its S&P 500 listing keeps the shares firmly embedded in the US healthcare sector.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 09:33.

Intuitive Surgical (US46120E6023) starts this Tuesday with a stable position on NASDAQ in the S&P 500 healthcare group. The focus for investors is the current analyst consensus on the ISRG shares, which reflects views on growth, valuation and sector role.

How analysts view ISRG today

Analyst coverage on Intuitive Surgical typically clusters in the large global houses that follow US medical technology, with ratings spread across Buy, Hold and occasionally Sell on published lists. Houses such as Goldman Sachs, JPMorgan and Morgan Stanley regularly include ISRG in their US medtech and robotics surgery coverage, with concrete 12-month price targets expressed in US dollars and explicit rating labels.

Consensus data services for US equities usually report both the distribution of ratings and an average target price for Intuitive Surgical based on published research, giving retail investors an overview of how the sell-side interprets growth prospects and capital allocation. On these platforms, ISRG often appears alongside US peers in medical devices and equipment, such as Medtronic, Stryker and Boston Scientific, highlighting its role within the broader surgical technology space.

What the current consensus implies

The consensus picture around Intuitive Surgical generally balances the company’s high margins and recurring revenue streams against valuation metrics such as forward price-to-earnings and price-to-sales multiples. In practice, this leads many analysts to frame the shares as a high-quality growth exposure in medical technology, but with sensitivity to broader moves in the S&P 500 and the US interest-rate environment.

Retail investors often use consensus tools from providers like MarketScreener or finanzen.net to see how many analysts rate Intuitive Surgical Buy and how that share has evolved over recent quarters, especially around earnings dates or major product updates. These platforms usually show the spread of price targets alongside the current NASDAQ trading price, allowing a direct comparison of implied upside or downside.

The product behind the stock

Intuitive Surgical’s business model centers on robotic-assisted minimally invasive surgery, with the da Vinci Surgical System as its flagship product. Hospitals purchase robotic systems and then generate recurring orders for instruments, accessories and service, which together create a mix of upfront capital sales and ongoing consumables and service revenues tied to procedural volume.

Where the stock trades today

Intuitive Surgical shares (US46120E6023) trade on NASDAQ in US dollars as part of the S&P 500 healthcare segment. As of 2026-06-30, 09:33, the current price and intraday performance need to be checked on a live quote service such as the NASDAQ official website or a real-time broker platform for exact levels.

Key data on the Intuitive Surgical shares

• Company: Intuitive Surgical, Inc.
• ISIN: US46120E6023
• WKN: 888024
• Ticker: ISRG
• Trading venue: NASDAQ
• Price (as of 2026-06-30, 09:33): live quote in USD required
• Market cap: latest published figure in USD (as of 2026)
• Sector / industry: Health Care Equipment & Supplies / Medical Devices
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice, a buy or sell recommendation, or a solicitation to trade Intuitive Surgical shares or any other financial instrument.